Serina Therapeutics, Inc. has announced a significant financing initiative, securing up to $30 million through a private placement aimed at advancing its clinical trial for SER-252, a treatment for advanced Parkinson's disease. The first tranche of this financing, amounting to $15 million, is expected to close on March 20, 2026, with a second tranche of up to $15 million anticipated to follow by April 30, 2026. The shares will be sold at a price of $2.25 each, reflecting a 68% premium over the closing price on March 17, 2026. Additionally, investors will receive warrants to purchase shares at an exercise price of $5.00, which could potentially raise an additional $33.3 million if fully exercised. This financing is crucial as it supports the ongoing single-ascending dose (SAD) registrational study under the 505(b)(2) NDA pathway. The company has already dosed the first patient in this trial, marking a pivotal moment in its development timeline. The involvement of Greg Bailey, M.D., who will take on the role of Co-Chairman of the Board, is expected to enhance the company's strategic direction and operational execution. This financing aligns with Serina's goal to generate clinical data that could transform treatment options for patients suffering from advanced Parkinson's disease, a condition affecting approximately 250,000 individuals in the U.S. and Europe whose symptoms remain inadequately controlled by current therapies.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.